10:12 AM EST - Avant Technologies Inc : Along with its JV partner, Ainnova Tech, Inc., a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence, today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company's submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review. Avant Technologies Inc
shares O.AVAI are trading up $0.04 at $0.44.
